Anti-HIV-1 Intermittent Drug Intensification in HIV-1-Infected Patients Naive for Antiretrovirals

Delta Coordinating Committee. Delta: a randomised double-blind controlled trial comparing combinations of zidovudine plus didanosine or zalcitabine with zidovudine alone in HIV-infected individuals. Lancet 1996; 348: 283–291.

Hammer S.M. , Katzenstein D.A. , Hughes M.D. , Gundacker H. , Schooley R.T. , Haubrich R.H. , Henry W.K. , Lederman M.M. , Phair J.P. , Niu M. , Hirsch M.S. , Merigan T.C. , & ACTG 175 Study Team. A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200 to 500 per cubic millimeter. New England Journal of Medicine 1996; 335: 1081–1090.

Saravolatz L.D. , Winslow D.L. , Collins G. , Hodges J.S. , Pettinelli C. , Stein D.S. , Markowitz N. , Reves R. , Loveless M.O. , Crane L. , Thompson M. , Abrams D. , & Investigators for the Terry Beirn Community Programs for Clinical Research on AIDS. Zidovudine alone or in combination with didanosine in HIV-infected patients with the acquired immunodeficiency syndrome or fewer than 200 CD4 cells per cubic millimeter. New England Journal of Medicine 1996; 335: 1099–1106.

Schooley R.T. , Ramirez-Ronda C. , Lange J.M.A. , Cooper D.A. , Lavelle J. , Lefkowitz L. , Moore M. , Larder B.A. , St Clair M.S. , Mulder J.W. , McKinnis R. , Pennington K.N. , Harrigan P.R. , Kinghorn I. , Steel H. , & Rooney J.F. Virologic and immunological benefits of initial combination therapy with zidovudine and zalcitabine or didanosine compared with zidovudine monotherapy. Journal of Infectious Diseases 1996; 173: 1354–1366.

Chow Y-K , Hirsch M. , Merrill D. , Bechtel L. , Eron J. , Kaplan J. , and D'Aquila R. Use of evolutionary limitations of HIV-1 multidrug resistance to optimize therapy. Nature 1993; 361: 650–654.

Mazzulli T. , Rusconi S. , Merrill D.P. , Moonis M. , D'Aquila R.T. , Chou T-C , & Hirsch M.S. Combination chemotherapy of HIV-1 infection in vitro: alternating versus continuous drug regimens. Antimicrobial Agents and Chemotherapy 1994; 38: 656–661.

Rusconi S. , Merrill D.P. , & Hirsch M.S. Inhibition of human immunodeficiency virus type 1 replication in cytokine-stimulated monocytes/macrophages by combination therapy. Journal of Infectious Diseases 1994; 170: 1361–1366.

1993 Revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. Morbidity and Mortality Weekly Report 1993; 41: 17.

Nguyen B. , Shay L.E. , Wyvill K.M. , Pluda J.M. , Brawley O. , Cohen R.B. , Whitcup S.M. , Venzon D.J. , Broder S. , & Yarchoan R. A pilot study of sequential therapy with zidovudine plus acyclovir, dideoxyinosine, and dideoxycytidine in patients with severe human immunodeficiency virus infection. Journal of Infectious Diseases 1993; 168: 810–817.

Yarchoan R. , Lietzau J.A. , Nguyen B.Y. , Brawley O.W. , Pluda J.M. , Saville M.W. , Wyvill K.M. , Steinberg S. W. , Agbaria R. , Mitsuya H. , & Broder S. A randomized pilot study of alternating simultaneous zidovudine and didanosine therapy in patients with symptomatic human immunodeficiency virus infection. Journal of Infectious Diseases 1994; 169: 9–17.